alpha-glutamyltryptophan has been researched along with Lung Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, J; Fukumoto, J; Gill, PS; Masood, R; Sharma, S; Smith, DL; Wei, W; Zhu, S | 1 |
| Blann, A; Christodoulos, K; Deplanque, G; Ganesan, TS; Harris, AL; Jones, PH; Madhusudan, S; Talbot, DC; Wellmann, S | 1 |
1 trial(s) available for alpha-glutamyltryptophan and Lung Neoplasms
| Article | Year |
|---|---|
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Dipeptides; Disease Progression; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neovascularization, Pathologic; Prospective Studies; Time Factors | 2004 |
1 other study(ies) available for alpha-glutamyltryptophan and Lung Neoplasms
| Article | Year |
|---|---|
Natural killer cell cytolytic activity is necessary for in vivo antitumor activity of the dipeptide L-glutamyl-L-tryptophan.
Topics: Angiogenesis Inhibitors; Animals; Cell Division; Cytoplasmic Granules; Cytotoxicity, Immunologic; Dipeptides; Flow Cytometry; Humans; Interferon-gamma; Interleukin-12; Killer Cells, Natural; Lung Neoplasms; Melanoma; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplasms, Experimental; Perforin; Pore Forming Cytotoxic Proteins; T-Lymphocytes; Tumor Cells, Cultured | 2003 |